Immunovant IMVT

$ 25.93 1.05%

Quarterly report 2024-Q3
added 11-07-2024

Immunovant Balance Sheet 2011-2024 | IMVT

Annual Balance Sheet Immunovant

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-375 M	-491 M	-397 M	-101 M	-	-25 K	-	-	-	-	-	-	-
Long Term Debt	-	47 K	1.22 M	2.24 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	138 K	1.17 M	1.14 M	1.18 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	48.6 M	43.3 M	44.5 M	18.8 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	48.6 M	43.3 M	45.7 M	21 M	15.3 M	-	380 K	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-826 M	-566 M	-355 M	-199 M	-91.2 M	-	-448	-	-	-	-	-	-	-
Total Assets	666 M	406 M	516 M	412 M	109 M	-	405 K	-	-	-	-	-	-	-
Cash and Cash Equivalents	635 M	377 M	494 M	400 M	101 M	6.98 M	-	-	-	-	-	-	-	-
Book Value	618 M	362 M	470 M	391 M	94.1 M	-	24.6 K	-	-	-	-	-	-	-
Total Shareholders Equity	618 M	362 M	470 M	391 M	94.1 M	7.34 M	-411 K	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Immunovant

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	47 K	306 K	614 K	-	1.22 M	-	-	1.97 M	2.24 M	2.39 M	2.68 M	2.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	66.7 M	45 M	48.6 M	32.1 M	40.3 M	51.4 M	43.3 M	41.6 M	32.4 M	-	45.7 M	38 M	30.3 M	22.5 M	21 M	18.9 M	15.5 M	22.5 M	15.3 M	14.8 M	4.36 M	4.12 M	6.49 M	380 K	-	380 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.02 B	-913 M	-826 M	-750 M	-699 M	-640 M	-566 M	-507 M	-444 M	-	-355 M	-308 M	-267 M	-229 M	-199 M	-170 M	-139 M	-118 M	-91.2 M	-70.7 M	307 K	182 K	-24.8 M	-448	-	-448	-448	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	516 M	590 M	666 M	711 M	292 M	351 M	406 M	456 M	428 M	-	516 M	543 M	567 M	388 M	412 M	433 M	454 M	290 M	109 M	127 M	118 M	117 M	13.8 M	405 K	-	405 K	405 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	473 M	560 M	635 M	691 M	270 M	330 M	377 M	433 M	406 M	427 M	494 M	527 M	559 M	379 M	400 M	422 M	444 M	280 M	101 M	124 M	1.61 M	1.91 M	6.98 M	325 K	-	325 K	325 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	449 M	545 M	618 M	679 M	252 M	300 M	362 M	415 M	396 M	-	470 M	505 M	536 M	366 M	391 M	414 M	438 M	268 M	94.1 M	112 M	113 M	113 M	7.34 M	24.6 K	-	24.6 K	405 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	449 M	545 M	618 M	679 M	252 M	300 M	362 M	415 M	396 M	436 M	470 M	505 M	536 M	366 M	391 M	414 M	414 M	438 M	268 M	112 M	-23.3 M	-12.1 M	-12.1 M	7.96 M	24.6 K	24.6 K	24.6 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency